Non-valvular Atrial Fibrillation
Conditions
Brief summary
The purpose of this study is to determine and compare the persistence rate of newly prescribed apixaban, rivaroxaban, dabigatran and VKAs in patients with NVAF.
Detailed description
Actual number of patients enrolled for UK : 15242 patients Actual number of patients enrolled for Germany : 22880 patients
Interventions
None listed
Sponsors
IMS Health
OXON Epidemiology
Bristol-Myers Squibb
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have an apixaban, rivaroxaban, dabigatran or VKA prescription during the study period * Are ≥18 years old at index date * Have ≥12 months of computerised medical data prior to index date * Have a record of AF on or ever prior to index date (index OAC prescription)
Exclusion criteria
* Have a record for a valvular condition (ie, rheumatic valvular disease and prosthetic valves) on or ever prior to index date * Have a history (ever prior to index date) of the Oral anticoagulant (OACs) which are prescribed during the study period
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Persistence rate of newly prescribed apixaban, rivaroxaban, dabigatran and vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation(NVAF) | 23 months for the UK and Germany, 25 months for France | We defined non-persistence in the databases as the absence of index prescription for twice the median prescription duration; and calculated cumulative incidence (95% CIs) of persistence at the end of follow-up and at different time points after treatment initiation (3, 6, and 12 months) |
Secondary
| Measure | Time frame |
|---|---|
| Demographic characteristics (Age, Gender, Smoking status, region of practice, data source) of patients with newly prescribed oral anticoagulants | 23 months for the UK and Germany, 25 months for France |
| Clinical characteristics (History of bleeding, myocardial infarction, stroke, Thromboembolism, congestive heart failure, vascular disease, hypertension, CHA2DS2-VASc score, HAS-BLED score, etc) of patients with newly prescribed oral anticoagulants | 23 months for the UK and Germany, 25 months for France |
| Adherence to newly prescribed oral anticoagulants based on Medication possession ratio (MPR) | 23 months for the UK and Germany |
| Compare persistence rates across oral anticoagulant therapies | 23 months for the UK and Germany, 25 months for France |
Outcome results
None listed